Compare Regeneron Pharmaceuticals Inc (REGN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Shell PLC — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Shell PLC trades at $95.6 (market cap $271.34B). The key difference: Shell PLC is far larger — about 3.3× Regeneron Pharmaceuticals Inc's market cap, and Shell PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals.
| REGN | SHEL | |
|---|---|---|
Market Cap | $83.43B | $271.34B |
Sector | Health | Energy |
52-Week High | $852.03 | $95.60 |
52-Week Low | $555.51 | $70.31 |
Enterprise Value | $78.14B | $313.04B |
Dividend Yield | 0.46% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Shell (SHEL) trades at $95.32, up 2.55% with strong bullish momentum as crude oil prices rally. The stock shows robust fundamentals with a P/E of 10.54 and net income margin of 8.76%, while recent Q2 2026 earnings beat expectations. Technical indicators signal bullish sentiment with the price near resistance at $96. Recent acquisitions including ARC Resources and strategic partnerships with BP expand Shell's deepwater footprint, driving growth prospects.
Outlook remains positive with analyst consensus price target of $101 (6% upside), supported by 61.5% buy ratings. Key risks include oil price volatility and geopolitical tensions, but strong cash flow generation and strategic expansions position SHEL for sustained growth. The current valuation appears attractive relative to earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
